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Summary
We have developed polyclonal and monoclonal antibodies against human membrane cofactor
protein (MCP) to use as tools to investigate the functions of MCP on intact nucleated cells.
Two human T cell lines, CEM and TALL, are CR1- and DAF- . Pretreatment of these cell
lines with M177 and polyclonal anti-MCP, which inhibit cofactor activity almost completely,
resulted in effective C3 deposition immediately following addition of these cells to Mgt+/
EGTA/human sera. The deposited C3 remained expressed partly on the cell surface and most
of them were gradually converted to Obi. Some of the deposited C3 were complexed with
membrane proteins, since 140- and 250-kD bands became significantly accumulated on SDS-
PAGE by treatment with the antibodies.
We next tested whether these C3-coated cells were damaged by complement-mediated cytolysis.
p18, an inhibitor of membrane attack complex (MAC) formation, was negative in TALL but
positive in CEM. TALL was lysed efficiently only by treatment with the polyclonal anti-MCP,
while CEM showed only slight lysis with the same treatment. Monoclonal antibodies to MCP,
including M177, caused only minimal cell destruction.
Based on these results, together with the fact that decay-accelerating factor (DAF) serves as
a factor for preventing C3 attack on human cells, we conclude that MCP and DAF cooperatively
protect host cells from C3 targeting and, in these T cell lines, MCP is sufficient for preventing
C3 deposition even without DAR After all, humancells undergo almost no autologous complement-
mediated cytolysis if they express at leastone ofthe functionally active inhibitors, MCP, DAF, or p18.
T
he deposition of C3 fragments is a critical step in com-
plement activation and subsequent complement-mediated
cell damage (1). In addition, bound C3 fragments serve as
ligands for C3 receptors to participate in lymphocyte- and
phagocyte-mediated cell damage (2, 3). Therefore activation
of C3 must be kept under strict control (4). In the classical
pathway, C3 can be activated only on cells where antibody
deposits. In the alternative pathway, most human tissue is
protected from autologous C3 deposition, whereas most for-
eign material is targeted by C3. The mechanism by which
target sites are distinguished, however, remains to be clarified
(5). Protection of host cells from C3 attack can be explained
in part by the presence of a membrane complement inhib-
itor, decay-accelerating factor (DAF).' Because of the absence
'Abbreviations used in this paper . DAF, decay-accelerating factor; MAC,
membrane attack complex; MCP, membrane cofactor protein; p18, an
inhibitor for MAC formation, recently identified as CD59; PNH,
paroxysmal nocturnal hemoglobinuria.
of DAF, paroxysmal nocturnal hemoglobinuria (PNH) ery-
throcytes amplify C3 deposition (6). In contrast, some human
cell lines, including Raji and Daudi, permit deposition of
human C3 on their surfaces (3, 7, 8), despite the fact that
they express DAF (3, 9), a finding that is inexplicable. Fur-
thermore, PNH leukocytes (10) and some human tumor cell
lines (9, 11), although they lack DAF, have only minimal
ability to trigger C3 deposition. Human nucleated cells must
possess another factor for regulation of C3 deposition be-
sides DAR
Membrane cofactor protein (MCP) has been shown in the
fluid phase to possess C3b-binding (12) and factor I-cofactor
activities (13) which may play important roles in regulation
of the alternative pathway. In the present study, we demon-
strated that MCP actually prevents C3 deposition on nucleated
host cells. We propose the evidence that on human nucleated
cells, DAF and MCP jointly engage in protection of host
cells, and in some cases, either one is sufficient to prevent
complement-mediated cell damage.
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Proteins, Antibodies, and Cells.
￿
Human MCP (14) and C3 (15)
were purified from a T cell line, HSB-2, and citrate phosphate-
dextrose-plasma, respectively, as previously described. Protein
labeling was performed with iodogen (16).
Rabbit polyclonalantibodiesto humanDAF (17) and MCP (18)
wereprepared as described. Monospecificityof these antibodieswas
further confirmed (19). Rabbit polyclonal antibody to human NZ-
microglobulin was a gift from Dr. J. P. Atkinson (Washington
University, St. Louis, MO). Mouse mAbs directed against human
MCP (9, 20) and C3b/C4b receptor (CR1) (20) were produced
as previouslynoted. These were purified using protein A-Sepharose
(20). Mouse mAbs against human DAF, IA10 (21), and against
p18 (22), an inhibitor of the formation of membrane attack com-
plex (MAC), 1F1(23), were generous gifts from Dr. T. Kinoshita
(Osaka University, Osaka), and Dr. M. Tomita (Showa University,
Tokyo), respectively. F(aV)2 of these antibodieswere prepared by
treatment with pepsin, by the method of Nisonoff (24).
Mouse mAb to human C3bi (which is specific to a neoepitope
for C3bi and C3dg, and does not react with C3, C3b, C3d, and
C3c) and human C3c (which reacts with C3b, C3bi, and C3c, but
not with C3d and C3dg)werepurchased from Cytotech (San Diego,
CA) and Genzyme Corp. (Boston, MA), respectively. Rabbit poly-
clonal antibody against human C3c was from Behringwerke (Mar-
burg, FRG).
Human T cell lines CEM and TALL, and an erythroblastoid
cell line, HEL, were gifts from the Japanese Cancer Research Re-
sources Bank (JCRA Tokyo). These were maintained in RPMI
1640 supplemented with 10% FCS (M.A. Bioproducts, Walkers-
ville, MD) and antibiotics. Cultures were kept in a 5% CO2/95%
air atmosphere at 37°C.
AssayforDeterminaam ofFuctorI-CofactorActmty
￿
A fluid phase
assaysystem was used (13). The buffer used in this assaywas 20 mM
phosphate buffer/0.02% NP-40, pH 6.2. 30 ngofMCP was prein-
cubatedwith various concentrations ofmAbs to MCP, M75, M160,
or M177, and then incubated with 0.5 jig of factor I and 10 hg
of methylamine-treated fluorescent-labeled C3, f-C3(MA) or
fluorescent-labeled C3b (f-0b) (25) for 3 h at 37°C. The reaction
was then stopped by the addition of 10 pl of 10% SDS and 3 pi
of 2-ME. The samples were analyzed by SDS-PAGE and the per-
cent a chain cleavage of the substrates was determined by spec-
trofluorometry as previously described (13, 14). The inhibitory effect
of the antibodieson the cleavage off-C3b was estimated assuming
that the degree of cleavage of a chains in the absence of the anti-
body was 100%.
Analysis of C3 Deposition on Tumor Cells.
￿
Two methods were
used to assess C3 deposition. In the first method, C3 fragments
deposited on the cell-surface were analyzed by flow cytometry (9).
Cells (106) were pretreated with about 25 pg of polyclonal anti-
bodies to MCP or nonimmune rabbit IgG and incubated with 50
p1 of Mgz+/EGTA/human serum and 150 pl of EGTA/GVBz+ for
90 min at 37°C. As a control, EDTA/human serumwas used in-
stead of Mgt+/EGTA/sera. The cells were washed twice in PBS
containing 2% BSA, and then,3 jig ofanti-C3c or anti-C3bi mAbs
were added as the fast antibody. After 45 min, thecells were again
washed twice in PBS/BSA, and 5 gg ofthe second antibody [(FITC-
labeled-F(ab')2 of goat anti-mouse IgG; Cappel Laboratories, Mal-
vern, PAJ) were added. The mixtures were allowed to stand for
45 min, washed twice, and analyzedby flow cytometry. When the
mAbs to MCP were used as the pretreatment reagents, rabbit poly-
clonal anti-C3c and FITC-labeled F(ab')2 of goat anti-rabbit IgG
(Cappel Laboratories) were used as the first and second antibodies,
respectively.
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The other method employed was to use SDS-PAGE and autora-
diography to analyze the deposited C3 fragments (9). Cells (106)
were pretreated with 30 t+g of M177 as described above. After
washing, 50 pl of "1I-labeled C3 (A2so. . - 3.0) were incubated
with 50 id of Mg2+/EGTAAerum or EDTA/serum, and 100 ;L1
of EGTA/GVBz+ or EDTA/GVB. The cells were washed thor-
oughly in PBS, solubilized with 1% NP-40/PBS containing 1 mM
PMSF, 10 mM EDTA, and 25 mM iodoacetamide, pH 7.4. The
samples were reduced, subjected to SDS-PAGE, and analyzed by
autoradiography.
FlouwcytometryAnalysisforAssessment ofSurface-expressed Comple-
ment Regulatory Proteins. Approximately 106 cells were incubated
for 45 min with 10-20 hg of the primary antibody, such as anti-
MCP (M177), anti-DAF (IA10), anti-CRI (31R), or anti-P18 (1F1),
together with 100 Al of EDTA plasma. 10 pg of mouse nonim-
mune IgG (Cappel) was used as a control. The cells were washed
in PBS containing 2% FCS, and treated with 5 pg of FITC-
conjugated second antibody in 100 pl of PBS/FCS and EDTA
plasma. After 45 min, the cells were washed twice with PBS and
fixedwith paraformaldehyde. The samples were analyzed on a FAC-
Scan (Becton Dickinson, Mountain View, CA) (18) within 1 wk.
The experiments were performed at room temperature.
SDS-PAGEandAutomdiography SDS-PAGE using 8% slab gels
was performed by the method ofLaemmli (26). Gels were stained,
destained, dried, and then exposed at -75°C. Cronex intensifier
screens (DuPont Co., Wilmington, DE) and XAR5 film (Eastman
Kodak Co., Rochester, NY) were used for autoradiography (17).
Cytolysis Assay.
￿
Cells (107) were incubated with 200 ACl of
"Cr (Amersham Corp., Arlington Heights, IL) in 400 Al of
RPMI for 60-120 min at 37°C (9). Although labeling efficiency
varied among the cell lines, 45,000-120,000 cpm were incorpo-
rated into 106 cells. The labeled cells were pretreated with anti-
bodies to MCP or nonimmune IgG and incubated with 15-30%
Mgz+/EGTA/serum or EIYTA/serum for 90 min at 37°C. Radio-
activity in the supernatants was measured in a gamma counter.
Results
Cell Lines on Which C3 Deposition Was Inducedby Treatment
with PolyclonalAnti-MCP. 24 human leukemia cell lines (9)
were treated with polyclonal anti-MCP and then human
Mgt+/EGTAAerum. The deposited C3 was assessed with
anti-human C3c or anti-human Obi mAb by flow cytom-
etry. Two T cell lines, CEM and TALL, became C3-sensitive
through treatment with anti-MCP (Fig. 1, B--D). C3 depos-
ited only slightly with the same treatment of most of the
other cell lines, including HEL (Fig. 1 A). The deposited
C3 was expressed on the cell surface and was detected by both
antibodies to C3c and Obi (Fig. 1). As reported previously
(9), little C3 was deposited on. CEM and TALL unless the
cells had been treated with anti-MCP (Fig. 1) . Treatment of
these cells with anti-02-microglobulin did not result in C3
deposition (not shown). In addition, no C3 was deposited
if Mgt+/EGTA/serum was substituted for EDTA serum.
Therefore, the observed C3 deposition was specific for anti-MCP
and the alternative complement pathway. The deposited C3
could be detected to a similar extent by both anti-0c and
anti-Obi, suggesting that the main product expressed on
the cells was Obi (Fig. 1 C, D) (27).
Complement Regulatory Proteins Distributed on CEM and
TALL.
￿
Using mAbs to CR1, DAF, and MCP, amounts
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flowcytometry. CR1 and DAF were not detected in CEM
and TALL (Fig. 2, A, B) . The absence of CR1 and DAF
in these cell lines was also supported by the protein A-ro-
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Therefore, effective C3 deposition occurred specifically on
the DAF-/CR1 - cells.
The level of p18, an inhibitor of the formation of MAC,
was assessed in these T cell lines by flowcytometry . CEM
possessed p18 whereas TALL did not (Fig. 2, C, D).
Figure 1.
￿
Deposition of C3-fragments on
TALL andCEMby treatmentwith polyclonal
antibody to MCP. HEL (A), CEM (B), and
TALL (C,D) were pretreated with rabbit IgG
(
￿
, - ---), polyclonal anti-MCP (- --),or
polyclonal anti-DAF (---), andincubated
with humanEDTA-serum (
￿
)or Mgz"/
EGTA/serum (-. ... -- -, ---). Thedepos-
itedC3 wasdetected with mAbs against human
C3c (A, B, D) or Obi (C), and subsequent
FITC-labeled goat anti-mouse IgG. After
washing, thecellswere analyzedby flow cytom-
103
￿
etry. Most of theothercell lines tested (9)ex-
hibited similar profiles to thoseof HEL (not
shown).
Figure 2.
￿
LevelsofCR1, MCP, DAF,
andp18on TALL andCEM. TALL and
CEM were incubated with mAbs to
CR1(31R) (...), MCP (M177) (- --),
DAF (IA10) (---), or p18 (1F1)
(
￿
). MouseIgGwasused as a con
trol. The bound antibodies were de-
tected with FITC-labeled goat anti-
mouseIgGandflowcytometry.(A, C)
CEM. (B, D) TALL.
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￿
Inhibition of cofactor activity ofMCP using mAbs against
MCP. MCP (30 ng) was preincubated with various concentrations ofM177
(/), M160 ("), or M75 (O). The mixtures were then incubated with
factor I and f-C3b . All samples were analyzed under reducing conditions
on SDS-PAGE . The percent cleavage of Cab was calculated based on the
results of densitometric analysis ofthese gels (25) . 30 ng ofMCP are -0 .5
pmol . The equimolar point of each mAb is indicated as a closed arrow .
Similar results were obtained using f-C3(MA) as a substrate (data not
shown).
Effect ofmAbs on Factor I-Cofactor Activity ofMCP and C3
Deposition on TALL. MCP acts as a cofactor for factor I to
generate C3bi from C3b in the fluid phase (13, 28) . We evalu-
ated the inhibitory activity of themAbs towards factor I-medi-
ated cleavage of C3b. Purified MCP (30 ng) was pretreated
with varying amounts of eachmAb to MCP, and incubated
with factor I and f-C3b . The inhibitory efficiency of these
B
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a
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Figure 5 .
￿
Analysis ofthe deposited fragments ofC3 onCEM and TALL
by SDS-PAGE followed by autoradiography. CEM (left) or TALL (right)
was preincubated with M177 (lanes 2, 4, 5, and 7), and then incubated
with EDTA/serum (lanes 2 and 5) or Mgt*/EGTA serum (lanes 3, 4, 6,
and 7) containing 12SI-labeled purified C3 . Lane 1 is the labeled C3 used
in this experiment. The arrowheads indicate C3 fragments complewd with
membrane proteins. The C3 fragments were identified according to previous
reports (9, 15) . BioRad molecular weight marker was used .
antibodies differed . The order of efficiency for inhibitory ac-
tivity towards the factor 1-cofactor activity of MCP was
M177>M75>M160 (Fig. 3) . More than 90% of MCP ac-
tivity was blocked by equimolar M177 .
We next examined the effect of F(ab')2 of the mAb on C3
deposition in the T cell lines. The mAbs also had the ability
to induce C3 deposition on these cells (Fig. 4) . Amounts
Figure 4.
￿
Deposition of human C3
onCEMand TALL using mAbs against
MCP. CEM (A) and TALL (B) were
pretreated with F(ab')2 of the mAbs
antibodies to MCP, and then incubated
with EDTA- of Mgt*/EGTA/serum
(see the inset table) . Bound C3 was de-
tected with polyclonal rabbit anti-
human C3c (see the Table) and FITC-
labeled goat anti-rabbit IgG . The last
antibody was added to all samples, al-
though not shown in the table.
Anti-Membrane Cofactor Protein-mediated C3 Deposition on Tumor Cells
preteatment serum 1st Ab
no Ab EGTA polyclonal rabbit
anti-human C3c
M177 EDTA polyclonal rabbit
anti-human C3c
M177 EGTA no Ab
M177 EGTA polyclonal rabbit
anti-human C3c
no Ab EGTA polyclonal rabbit
anti-human C3c
M75 EGTA polyclonal rabbit
anti-human C3c
M160 EGTA polyclonal rabbit
anti-human C3c
M177 EGTA polyclonal rabbit
anti-human C3cFigure 6 .
￿
Complement-mediated cytotoxicity induced by antibodies againstMCP. (A) Effect of polyclonal antibody. TALL and CEM were labeled
with s1Cr and pretreated with rabbit IgG or polyclonal rabbit anti-MCP . Thereafter, the samples were incubated with EDTA/serum or
Mgt'/EGTAAerum . The combinations of these reagents are shown in the figure. The liberated s1Cr in the supernatants was recovered and assayed
using a gamma counter. (B) Effect of mAbs . TALL were labeled with S1Cr and incubated with antibodies, as indicated in the figure . The samples
were then incubated with Mgz+/EGTA/serum. The released S'Cr was estimated as in A .
of deposited C3 were compared using the three antibodies
and TALL. The greatest amount was deposited on cells
pretreated with M177 . The order of efficiency for induction
ofC3 deposition wasM177>M75>M160, which is the same
order as that of the inhibitory activity for factor 1-mediated
C3b cleavage . Similar results were obtained with CEM (not
shown) .
Analysis ofthe Deposited C3 on the DAF-/CDI - T Cells.
To identify the C3 fragments deposited on M177-treatedCEM
and TALL, Mgt+/EGTA/serum containing 1151-labeled C3
was incubated with the M177-treated cells. EDTA/serum and
untreated cells were used as controls . The deposited fragments
of 1251-C3 were solubilized, reduced, and subjected to SDS-
PAGE followed by autoradiography. In the sample withM177
and Mgt+/EGTA/serum, prominent high molecular mass
bands of 250 and 140 kD together with u/u; u1, u2, and
(3 chains of C3 (Fig. 5) were accumulated . Although it is
unknown whether these C3 fragments were expressed on the
cell surface, the results from electrophoresis suggested that
C3/C3b and C3bi were the major forms detected in the NP-
40 extract of the anti-MCP-treated cells (Fig. 5) .
Complement-mediated Killing ofTALL which was Pretreated
with the mAbs to MCP . The effect of mAbs to MCP on
complement-mediated cytolysis was examined by "Cr-release
assay . All antibodies, including M177, killed<10% ofTALL
(Fig. 6 B) . A combination of the antibodies yielded about
30% 51Cr-release . On the other hand, polyclonal anti-MCP
released >60% of the SiCr (Fig. 6 A) . CEM showed <10%
release by pretreatment with either polyclonal or monoclonal
antibodies (Fig. 6, A and B) .
Discussion
This paper is the first to document thatMCP actually pro-
tects host cells from C3 targeting. This functional property
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was revealed using the DAF'/CR1 - human T cell lines,
which triggered efficient C3 deposition via the alternative
pathway by treatment with polyclonal or monoclonal anti-
MCP Little C3 was deposited on the cells that had been treated
with anti-/32-microglobuhn . C3 deposition was also induced
by two F(ab')2 of the mAb to MCP belonging to IgGi sub-
class (which lack the ability to activate complement), sug-
gesting that C3 deposition is independent ofthe complement-
activating effect of IgG. Of the mAbs tested, M177 caused
the most efficient C3 deposition . The order of efficiency of
these antibodies in the induction of C3-deposition was
M177>M75>M160, which is the same as that for inhibition
ofMCPmediated C3b-C3bi conversion . These results sug-
gest that the blocking ofMCP cofactor activity leads directly
to deposition of C3 on DAF-/CRI - cells via activation of
the alternative pathway.
MCP generally interacts withC3b on the same cell mem-
brane and not with C3b on other cells, and is said to be an
intrinsic factor I-cofactor protein, in contrast with the ex-
trinsic cofactor protein, CRI (14, 28) . DAF has been charac-
terized as an intrinsic complement regulator; although it does
not serve as a cofactor, it accelerates the decay of the conver-
tase complex (6, 29, 30) . Some human nucleated cells and
cell lines become susceptible to autologous C3 ifDAF is func-
tionally blocked (11) . Ofthe three cell-associated complement
regulatory molecules, DAF and MCP havenow been shown
to be engaged in protection of nucleated host cells from C3
attack . We favor the interpretation that the protective func-
tion of DAF and MCP is closely in conjunction with their
intrinsic activities but not with their mode ofinhibition . MCP
is distributed on all nucleated blood cells and cell lines (18,
31) . This may partly explain the well-characterized high re-
sistance of nucleated cells to complement attack (32) .
Extensive C3 amplification occurs on the DAF -/CR1 -
T cell lines CEM and TALL ifthe MCP activity is blocked ;the C3b-accepting sites on TALL and CEM should be sus-
ceptible to MCP. This means that the DAF -/CR1 - T cell
linescome to express acceptor molecules for autologousC3,
thereby allowing deposition of C3b. Some of the important
C3-accepting molecules are likely to be membrane proteins
forming complexes with fragments of labeled C3 that mi-
grate at 250 and 140 kD on SDS-PAGE.
It has been generally accepted that C3 deposition occurs
on foreign material but not on "self" tissue since the latter
does not express on its surface "activator" that can accept
C3b molecules and activate the alternative pathway (33, 34).
Ifthe activator represents acceptor molecules for Cab, as Mold
et al. suggested (35), the anti-MCP-treated CEM and TALL
must have activator, which accepts the initial C3b and assists
in extensive amplification of C3 deposition. According to
preceding work (33-35), together with the results of our
present study, most foreign cells effectively accept C3b via
their activator, which eventually results in cell damage; on
self cells, although most of them express activator on their
surface, the C3b initially deposited on it is essentially MCP-
and/or DAF-sensitive, thereby preventing activation of sub-
sequent C3, as well as its anchoring onto the cells. In other
words, since most C3b deposited on molecules of humancells
are not resistant to the inhibitors, they fail to amplify C3
activation. If this is the case, lack of inhibitors or a high ex-
pression of activator resistant to the action of inhibitors may
be representative conditions under which C3 deposition occurs
effectively on thecells. Indeed, C3 is able to deposit on human
Raji cells (3, 7-9) because they express CR2 (35) which is
known to evade the action of both MCP and DAF at least
on B cell lines (8, 35, 36), and on PNH erythrocytes because
they lack MCP and DAF (10, 21, 30, 37). Based on this hy-
pothesis, autologous cells can be converted to target cellsby
the function of activators or by modulating the inhibitors.
Deposited C3b appears to be largely converted to C3bi,
since antibodies specific to C3bi and C3c couldrecognize the
deposited C3 fragments to a similar extent (28) . These results
are only in partial agreement with those of the autoradio-
graphic analysis of the deposited C3 (Fig. 5), for reasons un-
known. As discussed in a previous paper (9), this discrepancy
may be partly due to the fact that some C3/C3b is unex-
pressed, as a result of internalization. Kinetic analysis indi-
cated that more than 30 min is required to reveal full C3bi
sites (Seya, T, manuscript in preparation), suggesting that
the C3 deposition and following C3b-C3bi conversion occur
gradually on the'cell surface under conditions in which MCP
is not functional. MCP is 50 times more active as a cofactor
than factor H (13) and is known to inactivate C3b instantly,
even in the fluidphase(14, 28). Most likely, this slow inacti-
vation of the deposited C3b is not due to the surviving MCP
but due to serum factor H . The fact that this slow inactiva-
tion of C3b did not impair amplification of C3 suggests the
inability of the fluidphaseregulatory factors to provide ade-
quate control of cell surface activation of C3.
Many reports have suggested that efficient C3-deposition
is induced on some tumor cells (7-9, 38-40). In most cases,
however, sensitizing antibody was needed for induction of
C3 deposition. This means that extensive C3 activationwould
be required to allowacceptor molecules to deposit C3b over-
coming regulatory factors. In this study, the blocking ofMCP
facilitated extensive C3 deposition even without sensitizing
antibodies. As shown in a previous paper (9), most tumor
cells and immature nucleated cells predominantly express MCP,
but little or no CR1. Furthermore, some lack DAF (9, 11).
Therefore, in complement-mediated cytotoxicity, a combi-
nation of anti-MCP with antibodies against tumor-associated
antigens may be more effective.
It has been reported that target cells could be eliminated
by CR1-mediated clearance (41), phagocytosis (2, 42, 43),
lymphocyte-mediated cytotoxicity (3, 44), and/or C9-mediated
immune-cytolysis (32). The last has been defined tradition-
ally as complement-mediated cytolysis. We next tested the
effect of anti-MCP on complement-mediated cytolysis. Only
polyclonal antibody-treated TALL were killed efficiently by
complement. Monoclonal anti-MCP also induced cell destruc-
tion, but only by 30% at most. The reasons for this dis-
crepancy between polyclonal and monoclonal antibodies re-
main unknown. Nucleated cells appear to have unique systems
to protect against MAC formation (32, 45-47). This may
explain in part the incomplete lysis of the monoclonal anti-
MCP-treated cells. CEM was barely killed by anti-MCP. This
finding seems to reflect the fact that TALL, but not CEM,
lacked p18.
DAF and p18 are both phosphatidylinositol (PI)-anchored
proteins (48-51) . A number of tumor cell lines are reported
to lack DAF, although it is unknown whether they lack p18.
A coincidental deficiency of these proteins may frequently
occur on tumor cells. These DAF -/p18- cells are to be dam-
aged only by anti-MCP treatment, which causes little or no
damage to normal cells expressing DAF and p18 (Matsumoto,
M., and T Seya,unpublished data). Therefore, the coincidental
dysfunction of the C3 regulatory/activating system and the
C9 regulatory system would lead to cell damage by autolo-
gous complement via the alternative complement cascade
resulting in immune cytolysis of human nucleated cells. We
have postulated that C3 deposition on autologous cells takes
place more frequently than cytolysis (9). The role and effect
of the C3 fragments deposited on autologous cells, in rela-
tion to other three mechanisms of cell destruction, should
prove to be of great importance in the elimination of tumor
cells.
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